Gattex (teduglutide) / Takeda - LARVOL DELTA

Reduction of Parenteral Nutrition in Children with Short Bowel Syndrome Treated with Teduglutide: Experience from the Czech Republic. (PubMed, Klin Padiatr) - "They also validate its safety and efficacy in this population. Despite the reduction in PN, improvements in weight were evident across the entire patient cohort."

Journal • Gastrointestinal Disorder • Pediatrics • Short Bowel Syndrome

Glucagon-Like Peptide-2 Therapy Outcomes Following Intestinal and Multivisceral Transplantation: A Multicenter Experience (WTC 2025) - "All patients received teduglutide, with 57% starting treatment prior to undergoing IT... GLP-2 therapy may play a beneficial role in intestinal adaptation and post-transplant recovery, potentially facilitating independence from TPN in IT and MVT recipients. Bowel obstruction appears to be the main complication leading to therapy discontinuation and occurred in the majority of patients undergoing GLP-2 therapy. Despite these challenges, survival outcomes were generally favorable, warranting further investigation into the long-term benefits and risks of GLP-2 therapy in transplant recipients."

Clinical • Colon Cancer • Colonic Polyps • Colorectal Cancer • Gastroenterology • Gastrointestinal Disorder • Septic Shock • Short Bowel Syndrome • Solid Tumor • Transplantation

Predictors of response and enteral autonomy in children with short bowel syndrome treated with teduglutide: a real-life multicentre cohort study. (PubMed, EClinicalMedicine) - "Between 01.06.2021 and 31.05.2023, we collected information on 104 children (64 males, 61.5%; 40 females, 38.5%) the median age at enrolment was 6.7 years old (IQR: 3.6-10.4); at 12 months' follow up after TED start 68 children achieved response (cumulative incidence: 70%, 95% CI 61%-79%), whereas complete PN weaning was achieved in 21 children (cumulative incidence: 22%, 95% CI 15%-31%). Even if limited by the real-life design of the study, these findings may guide a tailored indication for the use of teduglutide in children with short bowel syndrome. The European Society of Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) Networking grant."

Journal • Gastrointestinal Disorder • Hepatology • Liver Failure • Pediatrics • Short Bowel Syndrome

The impact and risk of teduglutide on reducing parenteral support in adult short bowel patients: UK tertiary centre data (BSG 2025) - "We also report the development of a vulval cancer occurring after only 7 months treatment. These encouraging results support results from previous studies and indicate significant benefits from tedaglutide use"

Clinical • Gastrointestinal Disorder • Gynecologic Cancers • Oncology • Short Bowel Syndrome • Solid Tumor • Vulvar Cancer

TAK-633-3009: A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome (clinicaltrials.gov) - P3 | N=13 | Recruiting | Sponsor: Takeda | Not yet recruiting ➔ Recruiting

Enrollment open • Gastrointestinal Disorder • Short Bowel Syndrome

Teduglutide in adults with short bowel syndrome and intestinal failure: A descriptive cohort study. (PubMed, JPEN J Parenter Enteral Nutr) - "Within an Australian cohort, teduglutide is effective at reducing parenteral support requirements in patients with short bowel syndrome-intestinal failure, although the effect onset and range remains heterogenous."

Journal • Gastrointestinal Disorder • Short Bowel Syndrome

Incorporating Caregiver Burden in Japans Cost-Effectiveness Evaluation: A Case Study of Teduglutide for Pediatric Short Bowel Syndrome (ISPOR 2025) - "This study aimed to integrate caregiver burden into cost-effectiveness evaluations within Japan’s healthcare system, using teduglutide, a recombinant human glucagon-like peptide 2 analogue that reduces PS dependence, as a case study. This study illustrates the practical steps for incorporating caregiver burden into Japan’s cost-effectiveness analyses, using pediatric SBS as an example. This expanded analysis captures a broader value, potentially guiding more informed resource allocation in Japan’s healthcare context."

Case study • Clinical • Cost effectiveness • HEOR • Gastrointestinal Disorder • Pediatrics • Short Bowel Syndrome

Identification of Pappalysin-2 (PAPP-A2), a modulator of Insulin-like Growth Factor-1 pathway, as a potential marker of teduglutide efficacy in patients with short bowel syndrome. (PubMed, Clin Nutr) - "We identified a new stakeholder, PAPPA-2, known to modulate IGF bioavailability, as playing a possible role in GLP-2 mechanism of action in human with SBS. We showed by association the existence of a greater spontaneous intestinal adaptation in SBS patients with a colon in continuity that could reduce sensitivity to teduglutide. Additionally, we suggest that initial PAPPA2 expression could serve as a predictive biomarker for teduglutide efficacy."

Journal • Gastrointestinal Disorder • Short Bowel Syndrome • IGF1 • PAPPA2

A RARE CLINICAL PRESENTATION AND DIFFUCULT MANAGEMENT IN AN INFANT WITH SEVERE CONGENITAL THROMBOPHILIA AND INTESTINAL FAILURE (ESPGHAN 2025) - "At the age of one year and stable enteral nutrition the child was stared on teduglutide, a glucagon-like peptide-2 analogue, with good effect. Conclusions Patients with SBS, IF and severe thrombophilia have a complicated course of the disease. They need a good multidisciplinary care in an expert centre but the prognosis remains unclear."

Clinical • Cardiovascular • Gastrointestinal Disorder • Genetic Disorders • Hematological Disorders • Infectious Disease • Septic Shock • Short Bowel Syndrome • Thrombosis

IMPACT OF TEDUGLUTIDE ON BODY COMPOSITION IN SHORT BOWEL SYNDROME PATIENTS (ESPGHAN 2025) - "Conclusions Treatment with GLP-2 analogues in SBS patients significantly impacts body composition and anthropometry, independent of reduced dependence on parenteral feeding. Further information is anticipated at the presentation of this work."

Clinical • Gastrointestinal Disorder • Rare Diseases • Short Bowel Syndrome

LET ESPGHAN SHINE INITIATIVE: DEFINING EARLY MARKERS OF RESPONSE AND ENTERAL AUTONOMY IN CHILDREN WITH SHORT BOWEL SYNDROME TREATED WITH TEDUGLUTIDE: A REAL-WORLD MULTICENTER STUDY (ESPGHAN 2025) - No abstract available

Biomarker • Clinical • Real-world • Real-world evidence • Gastrointestinal Disorder • Short Bowel Syndrome

A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome (clinicaltrials.gov) - P3 | N=13 | Not yet recruiting | Sponsor: Takeda

New P3 trial • Gastrointestinal Disorder • Short Bowel Syndrome

Development of a Mechanism of Action-Reflective Cell-Based Reporter Gene Assay for Measuring Bioactivities of Therapeutic Glucagon-like Peptide-2 Analogues. (PubMed, Molecules) - "Moreover, RNA sequencing reveals the multi-target regulatory effect of GLP-2 analogues. The establishment of this RGA provides a valuable tool for evaluating the potency of GLP-2 analogues and the screening of potential therapeutic drugs targeting to GLP-2 receptor."

Journal

Updates in Intestinal Failure Management. (PubMed, J Clin Med) - "Medical management involves individualized enteral and parenteral nutrition therapy, GLP-2 agonists (e.g., teduglutide) that promote mucosal growth, and drugs for symptom management such as antidiarrheals...An interdisciplinary approach involving surgeons, gastroenterologists, dietitians, nurses, and social workers is crucial in the management of these complex patients. Ultimately, a combination of nutritional, medical, and surgical management may be necessary to improve clinical outcomes in patients with IF."

Journal • Review • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Short Bowel Syndrome

LONG-TERM EFFECTIVENESS OF TEDUGLUTIDE IN ADULTS WITH SHORT BOWEL SYNDROME-ASSOCIATED INTESTINAL FAILURE: INTERIM ANALYSIS OF THE US SUBPOPULATION FROM A GLOBAL MULTICENTER REGISTRY STUDY (DDW 2025) - P | "Effectiveness may be influenced by duration of teduglutide exposure and duration of baseline PN/IV. Data collection is ongoing."

Clinical • Crohn's disease • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Short Bowel Syndrome

LONG-TERM EFFECTIVENESS OF TEDUGLUTIDE IN ADULTS WITH SHORT BOWEL SYNDROME-ASSOCIATED INTESTINAL FAILURE: INTERIM ANALYSIS FROM A GLOBAL MULTICENTER REGISTRY STUDY (DDW 2025) - P | "These real-world data support the long-term effectiveness of teduglutide for adult patients with SBS-IF. Data collection is ongoing."

Clinical • Gastrointestinal Disorder • Short Bowel Syndrome

LONG-TERM EFFECTIVENESS OF TEDUGLUTIDE FOR PATIENTS WITH CROHN'S DISEASE ON PARENTERAL SUPPORT FOR SHORT BOWEL SYNDROME ASSOCIATED WITH INTESTINAL FAILURE (DDW 2025) - "TED significantly reduced PS volume at 52 weeks in patients with CD associated with SBS-IF. Early reduction in PS volume may predict successful PS weaning."

Clinical • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Bowel Disease • Pain • Pneumonia • Respiratory Diseases • Short Bowel Syndrome • CRP

ELUCIDATING THE MECHANISM UNDERLYING THE ROLE OF GLP-2 IN MEDIATING INTESTINAL PROLIFERATION (DDW 2025) - "Importantly, the Teduglutide effect was blunted in Tamoxifen-treated Glp2r -deficient mice, supporting our hypothesis that the growth-promoting effect of GLP-2 on the small intestinal epithelium is mediated via Foxl1 + telocytes. Furthermore, telocytes are the target cell for GLP-2 action and mediate the proliferative effects of Teduglutide in the small intestinal epithelium."

Gastrointestinal Disorder • Short Bowel Syndrome • IGF1

Short Stature in Short Bowel Syndrome: Complex Interplay Between Nutrition and Growth (ESPE-ESE 2025) - "At two years and 5 months she began Teduglutide (analog to glucagon-like peptide 2) and at the age of three years and 6 months stopped parenteral nutrition...This case highlights the need of a multidisciplinary approach due to complex interplay between nutritional factors, and endocrine function in pediatric patients with SBS and short stature. Early recognition and targeted interventions, including optimizing nutrient absorption and addressing hormonal deficiencies, are essential to improving growth outcomes in children with chronic gastrointestinal conditions."

Gastrointestinal Disorder • Inflammation • Pediatrics • Short Bowel Syndrome • IGF1

Home parenteral nutrition: experience in a tertiary hospital (ESPE-ESE 2025) - "1 patient receiving Teduglutide treatment for 13 months... The age and indication for HPN in our series is similar to the literature. There was an improvement in the weight and BMI of the patients after HPN and we did not find statistically significant differences in the improvement of nutritional parameters, although there was a trend towards improvement."

Clinical • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Short Bowel Syndrome

Review of cost-effectiveness analysis to study pediatric intestinal failure and transplant. (PubMed, Intest Fail) - "Teduglutide and antimicrobial lock therapy provide two recent examples of treatments in the United States that came under scrutiny due to cost. We demonstrate the use of cost-effectiveness analysis to critically examine these treatments in the US as an example that may be adapted to various healthcare contexts worldwide. We then discuss the required steps to employ this methodology more effectively in pediatric intestinal failure."

HEOR • Journal • Gastrointestinal Disorder • Pediatrics • Short Bowel Syndrome • Transplantation

Teduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey. (PubMed, Bone Marrow Transplant) - "No specific teduglutide-related toxicity was observed. Our retrospective analysis suggests that teduglutide is safe and has activity in a fraction of patients with intestinal SR-aGVHD, which needs validation in a prospective trial."

Journal • Acute Graft versus Host Disease • Graft versus Host Disease • Immunology • Transplantation

Comprehensive analysis of adverse drug reactions associated with Teduglutide: post-marketing insights and safety implications. (PubMed, Expert Opin Drug Saf) - "Teduglutide is associated with significant ADRs necessitating vigilant monitoring while managing SBS patients, particularly for gastrointestinal health and infection risks. FAERS data limitations restrict causality determination, highlighting the need for further research to optimize safety."

Adverse drug reaction • Journal • P4 data • Cardiovascular • Gastrointestinal Disorder • Infectious Disease • Psychiatry • Short Bowel Syndrome

Drug-induced kidney stones: a real-world pharmacovigilance study using the FDA adverse event reporting system database. (PubMed, Front Pharmacol) - "The top 5 drugs most frequently linked to kidney stone cases were adalimumab (2,636 cases), infliximab (1,266 cases), interferon beta-1a (920 cases), sodium oxybate (877 cases), and teriparatide (836 cases). Notably, certain drugs like lansoprazole (ROR 7.2, 95% CI 6.62-7.84), Xywav (ROR 7.1, 95% CI 6.03-8.35), and teduglutide (ROR 5.54, 95% CI 4.83-6.36) showed significant risk signals...Our analysis of FAERS data revealed new risk signals for kidney stones not indicated in the labels of 33 drugs. Close monitoring is recommended when using these medications, and further research is needed to investigate the mechanisms behind drug-induced kidney stone formation."

Adverse events • Journal • Real-world evidence • Nephrology • Renal Calculi

A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada (clinicaltrials.gov) - P=N/A | N=52 | Completed | Sponsor: Takeda | Recruiting ➔ Completed | N=100 ➔ 52

Enrollment change • Trial completion • Gastrointestinal Disorder • Short Bowel Syndrome